Screening Tests
Transvaginal ultrasonography and serum cancer antigen (CA)-125 testing are readily available procedures and commonly suggested screening methods. The bimanual pelvic examination is often conducted (usually annually) in part to screen for ovarian cancer, although its effectiveness and harms are not well-known and were not a focus of this review.
The evaluation of abnormal test results consists of either repeated testing or, frequently, removal of one or both of the ovaries by means of laparoscopy or laparotomy.
Treatment
Treatment of ovarian carcinoma includes surgical treatment (debulking) and intraperitoneal or systemic chemotherapy.
Useful Resources
In its recommendation on genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility, the USPSTF recommends that women with a family history indicating that they are at risk for a deleterious mutation be referred for genetic counseling and testing. More information on this recommendation can be found at www.uspreventiveservicestaskforce.org .
Definitions: What the U.S. Preventive Services Task Force (USPSTF) Grades Mean and Suggestions for Practice

Grade
Grade Definitions Suggestions for Practice
A The USPSTF recommends the service. There is high certainty that the net benefit is substantial.
Offer or provide this service.
B
The USPSTF recommends the service. There is high certainty that the net benefit is moderate or there is moderate certainty that the net benefit is moderate to substantial.
C
Note: The following statement is undergoing revision.
Clinicians may provide this service to selected patients depending on individual circumstances. However, for most individuals without signs or symptoms there is likely to be only a small benefit from this service.
Offer or provide this service only if other considerations support offering or providing the service in an individual patient.
D
The USPSTF recommends against the service. There is moderate or high certainty that the service has no net benefit or that the harms outweigh the benefits.
Discourage the use of this service.
I Statement
The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of the service. Evidence is lacking, of poor quality, or conflicting, and the balance of benefits and harms cannot be determined.
Read the "Clinical Considerations" section of the USPSTF Recommendation Statement (see "Major Recommendations" field). If the service is offered, patients should understand the uncertainty about the balance of benefits and harms.
USPSTF Levels of Certainty Regarding Net Benefit
Definition: The USPSTF defines certainty as "likelihood that the USPSTF assessment of the net benefit of a preventive service is correct." The net benefit is defined as benefit minus harm of the preventive service as implemented in a general, primary care population. The USPSTF assigns a certainty level based on the nature of the overall evidence available to assess the net benefit of a preventive service.
Level of Certainty
Description
High
The available evidence usually includes consistent results from well-designed, well-conducted studies in representative primary care populations. These studies assess the effects of the preventive service on health outcomes. This conclusion is therefore unlikely to be strongly affected by the results of future studies.
Moderate The available evidence is sufficient to determine the effects of the preventive service on health outcomes, but confidence in the estimate is constrained by factors such as:
The number, size, or quality of individual studies Inconsistency of findings across individual studies Limited generalizability of findings to routine primary care practice Lack of coherence in the chain of evidence As more information becomes available, the magnitude or direction of the observed effect could change, and this change may be large enough to alter the conclusion.
Low
The available evidence is insufficient to assess effects on health outcomes. Evidence is insufficient because of: 
Study Selection
One of two reviewers reviewed the titles and abstracts of retrieved studies; two reviewers independently read and assessed articles for abstraction based on inclusion and exclusion criteria. For the literature on benefits of screening, AHRQ staff included controlled trials as well as systematic reviews and meta-analyses. For harms, they included controlled trials, cohort studies, case-control studies, and case series, as well as systematic reviews and meta-analyses. They excluded editorials and guidelines.
Results
The literature search returned 64 potentially relevant titles that were entered into a reference database. A total of 60 articles were excluded after title and abstract review, and two more were excluded after full article review. AHRQ staff excluded 18 studies not related to ovarian cancer, 34 studies that did not describe screening, two studies that described no relevant outcomes, two studies that described a high-risk or special patient population, and three studies that were an inappropriate study type. One additional report of a prospective screening study that was included in the evidence for harms was identified after a supplemental search of MEDLINE for publications by selected authors.
Limitations
The search strategy employed may have missed some smaller studies on the benefits and harms of screening for ovarian cancer.
Bridge Evidence Update Methods
PubMed, MEDLINE, and the Cochrane Central Register of Controlled Trials were searched to identify new, substantial evidence on ovarian cancer screening published between October 15, 2007 and July 26, 2011. Searches were restricted to English-language studies in core clinical journals and focused largely on trials following a search strategy developed by AHRQ. The search strategy was modified slightly to include a wider range of studies in more recent years.
The initial literature search yielded 848 titles and/or abstracts. Two individuals reviewed titles and abstracts to identify potentially relevant articles. Thirty articles were identified as potentially eligible and reviewed in full. Of these, articles were excluded for the following (nonmutually exclusive) reasons: not related to ovarian cancer (n=1), not related to screening (n=21), did not include relevant outcomes (n=4), focused on a high-risk or special patient population (n=2), and not an appropriate study type (n=3). Thus, four articles from three studies were identified for inclusion in this report.
Results
Three randomized, controlled trials published results on ovarian cancer screening during the period covered by this review. Only one study-the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial-presented information on mortality. The other two studies presented information on screening characteristics and harms related to false-positive screening results.
Limitations
The search strategy employed for the review was designed to identify substantial new studies, particularly randomized trials, published in indexed journals. Thus, this is not a comprehensive review of the literature.
Bridge Evidence Update
Four articles from three studies were identified for inclusion. No studies were included for data abstraction on the benefits of screening for ovarian cancer. For data on the harms of screening, one reviewer abstracted information on sample size, number of patients with abnormal test results, and follow-up evaluation of abnormal tests, including surgical biopsy and cancer outcomes.
Data Synthesis and Analysis
Data from the included studies were not able to be synthesized due to heterogeneity in patient populations and study design, but are summarized qualitatively in narrative format.
Bridge Evidence Update
Findings from the three trials included in the review were summarized.
Methods Used to Formulate the Recommendations Balance Sheets
Expert Consensus
Description of Methods Used to Formulate the Recommendations
The U.S. Preventive Services Task Force (USPSTF) systematically reviews the evidence concerning both the benefits and harms of widespread implementation of a preventive service. It then assesses the certainty of the evidence and the magnitude of the benefits and harms. On the basis of this assessment, the USPSTF assigns a letter grade to each preventive service signifying its recommendation about provision of the service (see Table below ). An important, but often challenging, step is determining the balance between benefits and harms to estimate "net benefit" (that is, benefits minus harms). Preventive Services Task Force after assessing certainty and magnitude of net benefit of the service (see the "Rating Scheme for the Strength of the Recommendations" field).
The overarching question that the Task Force seeks to answer for every preventive service is whether evidence suggests that provision of the service would improve health outcomes if implemented in a general primary care population. For screening topics, this standard could be met by a large randomized, controlled trial (RCT) in a representative asymptomatic population with follow-up of all members of both the group "invited for screening" and the group "not invited for screening."
Direct RCT evidence about screening is often unavailable, so the Task Force considers indirect evidence. To guide its selection of indirect evidence, the Task Force constructs a "chain of evidence" within an analytic framework. For each key question, the body of pertinent literature is critically appraised, focusing on the following 6 questions: The next step in the Task Force process is to use the evidence from the key questions to assess whether there would be net benefit if the service were implemented. In 2001, the USPSTF published an article that documented its systematic processes of evidence evaluation and recommendation development. At that time, the Task Force's overall assessment of evidence was described as good, fair, or poor. The Task Force realized that this rating seemed to apply only to how well studies were conducted and did not fully capture all of the issues that go into an overall assessment of the evidence about net benefit. To avoid confusion, the Task Force has changed its terminology. Whereas individual study quality will continue to be characterized as good, fair, or poor, the term certainty will now be used to describe the Task Force's assessment of the overall body of evidence about net benefit of a preventive service and the likelihood that the assessment is correct. Certainty will be determined by considering all 6 questions listed above; the judgment about certainty will be described as high, moderate, or low.
In making its assessment of certainty about net benefit, the evaluation of the evidence from each key question plays a primary role. It is important to note that the Task Force makes recommendations for real-world medical practice in the United States and must determine to what extent the evidence for each key question-even evidence from screening RCTs or treatment RCTs-can be applied to the general primary care population. Frequently, studies are conducted in highly selected populations under special conditions. The Task Force must consider differences between the general primary care population and the populations studied in RCTs and make judgments about the likelihood of observing the same effect in actual practice.
It is also important to note that one of the key questions in the analytic framework refers to the potential harms of the preventive service. The Task Force considers the evidence about the benefits and harms of preventive services separately and equally. Data about harms are often obtained from observational studies because harms observed in RCTs may not be representative of those found in usual practice and because some harms are not completely measured and reported in RCTs.
Putting the body of evidence for all key questions together as a chain, the Task Force assesses the certainty of net benefit of a preventive service by asking the 6 major questions listed above. The Task Force would rate a body of convincing evidence about the benefits of a service that, for example, derives from several RCTs of screening in which the estimate of benefits can be generalized to the general primary care population as "high" certainty (see the "Rating Scheme for the Strength of Recommendations" field). The Task Force would rate a body of evidence that was not clearly applicable to general practice or has other defects in quality, research design, or consistency of studies as "moderate" certainty. Certainty is "low" when, for example, there are gaps in the evidence linking parts of the analytic framework, when evidence to determine the harms of treatment is unavailable, or when evidence about the benefits of treatment is insufficient. 
Grade Grade Definitions Suggestions for Practice
B
C
Note: The following statement is undergoing revision.
D
I Statement
USPSTF Levels of Certainty Regarding Net Benefit
Level of Certainty Description
High
Low
The available evidence is insufficient to assess effects on health outcomes. Evidence is insufficient because of:
The limited number or size of studies Important flaws in study design or methods Inconsistency of findings across individual studies Gaps in the chain of evidence Findings not generalizable to routine primary care practice A lack of information on important health outcomes More information may allow an estimation of effects on health outcomes.
Level of Certainty Description
Cost Analysis
A formal cost analysis was not performed and published cost analyses were not reviewed.
Method of Guideline Validation
Comparison with Guidelines from Other Groups
External Peer Review
Internal Peer Review
Description of Method of Guideline Validation
Peer Review. Before the U.S. Preventive Services Task Force (USPSTF) makes its final determinations about recommendations on a given preventive service, the Evidence-based Practice Center and the Agency for Healthcare Research and Quality send a draft evidence review to 4 to 6 external experts and to Federal agencies and professional and disease-based health organizations with interests in the topic. The experts are asked to examine the review critically for accuracy and completeness and to respond to a series of specific questions about the document. After assembling these external review comments and documenting the proposed response to key comments, the topic team presents this information to the USPSTF in memo form. In this way, the USPSTF can consider these external comments before it votes on its recommendations about the service. Draft recommendation statements are then circulated for comment among reviewers representing professional societies, voluntary organizations, and Federal agencies, as well as posted on the Task Force Web site for public comment. These comments are discussed before the final recommendations are confirmed.
Response to Public Comment. A draft version of this recommendation statement was posted for public comment on the USPSTF Web site from 10 April to 8 May 2012. In response to comments, the USPSTF clarified language describing what is meant by increased risk for ovarian cancer, what is known about ovarian cancer screening in women with a family history of the disease, and the diagnostic pathway for abnormal screening results.
Commenters also asked about other potential screening methods and about the potential role of symptoms in the earlier detection of ovarian cancer. The USPSTF noted that the OvaDx test for is not currently approved by the U.S. Food and Drug Administration for clinical use in ovarian cancer screening and there is currently limited evidence to assess the ultimate health effects of other potential screening tests for ovarian cancer. The USPSTF also noted that a search for data on potential role of symptoms to guide earlier detection of ovarian cancer was outside the scope of the commissioned systematic evidence review used to inform this recommendation statement. However, a literature search reveals that there may be important inherent challenges related to the reliability of incorporating these nonspecific symptoms into ovarian cancer screening and diagnostic testing decisions (see the "Response to Public Comments" section in the original guideline document for additional detail).
Comparison with Guidelines from Other Groups. Recommendations for screening from the following groups were discussed: the American Congress of Obstetricians and Gynecologists and the American Cancer Society.
Evidence Supporting the Recommendations 
Qualifying Statements Qualifying Statements
The U.S. Preventive Services Task Force (USPSTF) makes recommendations about the effectiveness of specific clinical preventive services for patients without related signs or symptoms. It bases its recommendations on the evidence of both the benefits and harms of the service and an assessment of the balance. The USPSTF does not consider the costs of providing a service in this assessment. The USPSTF recognizes that clinical decisions involve more considerations than evidence alone. Clinicians should understand the evidence but individualize decision making to the specific patient or situation. Similarly, the USPSTF notes that policy and coverage decisions involve considerations in addition to the evidence of clinical benefits and harms. Recommendations made by the USPSTF are independent of the U.S. government. They should not be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.
Implementation of the Guideline Description of Implementation Strategy
The experiences of the first and second U.S. Preventive Services Task Force (USPSTF), as well as that of other evidence-based guideline efforts, have highlighted the importance of identifying effective ways to implement clinical recommendations. Practice guidelines are relatively weak tools for changing clinical practice when used in isolation. To effect change, guidelines must be coupled with strategies to improve their acceptance and feasibility. Such strategies include enlisting the support of local opinion leaders, using reminder systems for clinicians and patients, adopting standing orders, and audit and feedback of information to clinicians about their compliance with recommended practice.
In the case of preventive services guidelines, implementation needs to go beyond traditional dissemination and promotion efforts to recognize the added patient and clinician barriers that affect preventive care. These include clinicians' ambivalence about whether preventive medicine is part of their job, the psychological and practical challenges that patients face in changing behaviors, lack of access to health care or of insurance coverage for preventive services for some patients, competing pressures within the context of shorter office visits, and the lack of organized systems in most practices to ensure the delivery of recommended preventive care.
Dissemination strategies have changed dramatically in this age of electronic information. While recognizing the continuing value of journals and other print formats for dissemination, the USPSTF will make all its products available through its Web site . The combination of electronic access and extensive material in the public domain should make it easier for a broad audience of users to access USPSTF materials and adapt them for their local needs. Online access to USPSTF products also opens up new possibilities for the appearance of the annual, pocket-size Guide to Clinical Preventive Services.
To be successful, approaches for implementing prevention have to be tailored to the local level and deal with the specific barriers at a given site, typically requiring the redesign of systems of care. Such a systems approach to prevention has had notable success in established staff-model health maintenance organizations, by addressing organization of care, emphasizing a philosophy of prevention, and altering the training and incentives for clinicians. Staff-model plans also benefit from integrated information systems that can track the use of needed services and generate automatic reminders aimed at patients and clinicians, some of the most consistently successful interventions. Information systems remain a major challenge for individual clinicians' offices, however, as well as for looser affiliations of practices in network-model managed care and independent practice associations, where data on patient visits, referrals, and test results are not always centralized. 
Implementation Tools
